First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.

doi:10.1016/j.ejca.2024.113556

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.

European journal of cancer (Oxford, England : 1990) - 1 Mar 2024

Blasi Miriam, Kuon Jonas, Lüders Heike, Misch Daniel, Kauffmann-Guerrero Diego, Hilbrandt Moritz, Kazdal Daniel, Falkenstern-Ge Roger-Fei, Hackanson Björn, Dintner Sebastian, Faehling Martin, Kirchner Martina, Volckmar Anna-Lena, Kopp Hans-Georg, Allgäuer Michael, Grohé Christian, Tufman Amanda, Reck Martin, Frost Nikolaj, Stenzinger Albrecht, Thomas Michael, Christopoulos Petros

Abstract excerpt

BACKGROUND: The efficacy of checkpoint inhibitors for non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METΔ14ex) remains controversial. MATERIALS AND METHODS: 110 consecutive METΔ14ex NSCLC patients receiving first-line chemotherapy (CHT) and/or immunotherapy (IO) in 10 German centers between 2016-2022 were analyzed. RESULTS: Combined CHT-IO was given to 35/110 (32%) patients, IO alone to 43/110...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Exons

Share to MET gene

Share to Immunotherapy

Share to Lung Neoplasms

Share to Mutation

Share to Tumor Suppressor Protein p53

Source

Open in PubMed

Identifiers

PMID: 38271745
DOI: 10.1016/j.ejca.2024.113556

Genes

TP53
MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.PMID 38271745Read ↗

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future ChallengesSemantic proximity Read ↗

Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals.Semantic proximity Read ↗

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.Semantic proximity Read ↗

Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations.Semantic proximity Read ↗

Tepotinib in patients with MET exon 14 skipping non-small cell lung cancerSemantic proximity Read ↗

MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.Semantic proximity Read ↗

The Treatment of a New Entity in Advanced Non-small Cell Lung Cancer: MET Exon 14 Skipping Mutation.Semantic proximity Read ↗

First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLCSemantic proximity Read ↗

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.Semantic proximity Read ↗

Targeted therapeutic options in early and metastatic NSCLC-overview.Semantic proximity Read ↗

MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.Semantic proximity Read ↗

Real world experience with MET inhibitors in MET exon 14 skipping mutated non-small cell lung cancer: largest Indian perspectiveSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.